FDA green-lights Infinitt cardiac display, analysis package

Lisa Fratt | | Health Imaging | Screening
Infinitt's Xelis Cardiac, a 2D, 3D and 4D display and analysis tool for coronary CT angiography and left ventricle analysis, has received clearance from the FDA.

Xelis Cardiac can be used as an integrated system with Infinitt's web-based PACS or as a stand-alone system, allowing any third-party PACS user to query, view and analyze DICOM studies.

The package includes three diagnostic modules: vessel analysis, functional ventricle analysis and calcium scoring.

Infinitt, the Phillipsburg, N.J.-based developer of image and information management systems for healthcare, added that the Xelis Calcium Scoring system is currently under FDA review.

 

 


Lisa Fratt

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.